A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
The purpose of this study is to see whether an HIV vaccine, ALVAC vCP205, is safe and can prevent HIV infection. The vCP205 vaccine will be tested with another vaccine, gp160MN/LAI-2.
Biological: gp160 MN/LAI-2
Biological: ALVAC-HIV MN120TMG (vCP205)
|Study Design:||Endpoint Classification: Safety Study
Primary Purpose: Prevention
|Official Title:||A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults|
|Study Start Date:||April 1998|
This study consists of 2 parts:
Part A: Dose-escalation protocol using oligomeric gp160MN/LAI-2. Part B: Placebo-controlled, randomized, double-blind (within arm) study of vCP205 priming with gp160MN/LAI-2 boosting.
Volunteers are followed for at least 1 year.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004579
|United States, Maryland|
|Walter Reed Army Institute of Research|
|Rockville, Maryland, United States|
|Principal Investigator:||Jerome H. Kim|